Skip to main content

Table 1 Patient’s characteristics

From: Arsenic trioxide (As2O3) as a maintenance therapy for adult T cell leukemia/lymphoma

Patient

Sex

Age at diagnosis

Clinical subtype

p53 activity

First line treatment

Interval between induction therapy and As2O3 consolidation (months)

Disease status at time/after of A2So3

Treatment duration (weeks)

OS since diagnosis (months)

Death

OS since arsenic (months)

Duration of response since As2O3 (months)

Progression

ATL 6

M

51.6

Chronic

F

AZT-IFN-VP16

24.4

SD/SD

4

53

Yes

28

22

Yes

ATL 9

M

50.6

Chronic

F

CHOP like

20.1

CR/CR

6

48

Yes

28

25

Yes

ATL 11

M

27.7

Chronic

F

LSG 15 + AZT-IFN

13.2

VGPR/CR

6

97

Yes

83

73

Yesa

ATL 7

F

59.8

Acute

F

CHOP like

6.2

PD/PD

4

8

Yes

1

NA

Yes

ATL 14

F

35.1

Acute

NF

Alemtuzumab-CHOP

2.2

CR/CR

4

12

Yes

10

5

Yes

ATL 43

F

66.3

Lymphoma

F

CHOP like

6.3

CR/CR

8

19

Yes

12

5

Yes

ATL 44

F

54.8

Lymphoma

F

CHOP like

3.8

VGPR/CR

8

36

Yes

32

29

Yes

ATL 64

M

63.1

Lymphoma

ND

CHOP/DHAOx

13

CR/CR

8

65

No

51

51

No

ATL 65

M

54.4

Lymphoma

ND

CHOP

4

PR/PR

16

41

Yes

36

10

Yes

  1. M, male; F, female; CHOP, cyclcophosphamide, doxorubicine, oncovin, prednisone; DHAOx, dexamethasone, aracytine high dose, oxaliplatine; CR, complete response; PR, partial response; VGPR, very good partial response; SD, stable disease; PD, progressive disease
  2. F, functional; NF, non functional (this patient was found to have a p.V274A variant of TP53)
  3. aClone switch